secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001628280-24-037174
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo shareholders approve equity plan increase to 3.55M shares, ESPP, and elect directors
--------------------------------------------------------------------------------

- Stockholders approved Fourth Amended and Restated 2016 Equity Incentive Plan, increasing share reserve to 3,548,882 shares with automatic annual increases through 2034.
- Stockholders also approved Amended and Restated Employee Stock Purchase Plan, reserving 234,878 shares with automatic annual increases through 2034.
- All seven director nominees were elected: June Almenoff, Mitchell Chan, Jonathan Goldman, Aaron Kantoff, Gilla Kaplan, Garry Neil, Samantha Truex.
- Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.
- Proposal to approve issuance of shares for Series C Preferred conversion, warrant exercise, and AlmataBio milestone obligations was approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/0001628280-24-037174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/avtx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-037174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer